06 December 2022
We couldn’t be happier to have been a part of the latest financing round for Vaxxas – a company that OneVentures has been supporting for a very long time, with good reason.
The development of the nanopatch to deliver needle-free vaccines has massive global potential. We are now witnessing the pivotal stages in the company’s development: an in-human clinical trial that is now actively recruiting and the commercialisation of production through building a new manufacturing centre in Brisbane.
It is extremely gratifying to see companies grow from early stages to being on the cusp of changing how vaccines are delivered around the world. Read the full article in the Australian Financial Review
Posted in — AFR